Spoke with the CYC many years ago... very niche targets with PE...

Spoke with the CYC many years ago... very niche targets with PE at the time.. all the factors previously mentioned are valid, also the biggest take I took is the fact, the technology is around for 30+ years with well over 60+ countries implemented .... revenue for the first half of this year is only A$16.5m and still at loss making with cash balance of less than $16million and trading little over A$250million mkt cap..... sure its finally in the US... and targeting other lung diseases in the future.. I don't see it as a big threat to 4DX, but it's a competitor one way or another....but with a very slow revenue growth and grind.... eventually will be profitable trading at reasonable P/E .. but nothing like what 4DX can do IF and WHEN it signs up VA/DOD contracts..... ALL IMO..